Observations on a New Example of the A(m) Phenotype which
Demonstrates Reduced A Secretion

Darnborough, J.; Voak, D.; Pepper, R.M.

doi:10.1159/000465635

Cited by 5 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our opinion, even in absence of more genetic data, the immuno logical criteria published by Gundolf and Andersen [9] about their subject IM (small amount of B substance secreted in the saliva and absence of demon strable anti-B in the eluates of IM RBC incubated with anti-B sera) do agree with the description of the first case of By phenotype. On the contrary, the phenotypes described by Liotta et al [ 17] and Salmon et al [25] are respectively known as Bm and B0 and should correspond to phenotypes named 'Bm' the transmission of which as an ABO allele has been demonstrated in the family reported by Ikemoto et al [14], Darnborough et al [4] have suggested that in Ay subjects, only the for mation of glycolipid A substance is blocked. However, the results of en zyme conversion of the Ay RBC by various glycosyltransferases seem to show that the Ay red cell membrane behave normally.…”

Section: Discussionmentioning

confidence: 97%

Assay of α-TV-Acetylgalactosaminyltransferases in Human Sera

Cartron¹,

Gerbal²,

Badet³

et al. 1975

Vox Sanguinis

View full text Add to dashboard Cite

The study of the α-N-acetylgalactosaminyltransferase in the sera of 19 individuals belonging to the rare A(m) blood group makes it possible to confirm the heterogeneity of this phenotype established on genetical and immunological criteria. Two groups of subjects, A(m) and A(y), can be distinguished. For the individuals of the first group, named A(m), 15 samples (7 families) have been studied, the phenotype is inherited as an allele at the ABO locus. 14 of these subjects, have an α-N-acetylgalactosaminyltransferase whose kinetic properties were similar to those of A(1) subjects. In one family, however, the A transferase detected is of the A(2) type. On a quantitative level, the enzyme activities of these sera only reached 30-50% of the average value observed for A(1) or A(2) subjects, respectively. These facts suggest the existence of a genetic inhibitor, possibly linked to the ABO locus, preventing either an A(1) or A(2) gene from acting at the level of some cellular lines and leading therefore to the recognition of phenotypes named A(m)^A1 and A(m)^A2. On the contrary, under the experimental conditions used, no α-N-acetylgalactosaminyltransferase activity was detected among the four individuals of the second group, named Ay by Weiner et al. [37], and whose appeareance in siblings results from the action of a recessive modifying y^A gene.

show abstract

Section: Discussionmentioning

confidence: 97%

Assay of α-TV-Acetylgalactosaminyltransferases in Human Sera

Cartron¹,

Gerbal²,

Badet³

et al. 1975

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…DARNBOROUGH et al [4] have suggested that in Ay subjects, only the formation of glycolipid A substance is blocked. However, the results of enzyme conversion of the A, RBC by various glycosyltransferases seem to show that the A, red cell membrane behave normally.…”

Section: Discussionmentioning

confidence: 99%

“…At the genetic level, two groups of healthy Am individuals can be distinguished : (1) The first group of individuals belong to the phenotype first described by WEINER et al [37], then by DODD and GILBEY [5] and more recently by DARNBOROUCH et al [4]. This phenotype results from the action of a recessive y A gene independent of the ABO locus, present in double dose, which hinders the erythrocyte expression of the A antigen.…”

Section: Introductionmentioning

confidence: 99%

Assay of α‐N‐Acetylgalactosaminyltransferases in Human Sera: Further Evidence for Several Types of A_m Individuals

et al. 1975

View full text Add to dashboard Cite

The study of the alpha-N-acetylgalactosaminyltransferase in the sera of 19 individuals belonging to the rare Am blood group makes it possible to confirm the heterogeneity of this phenotype established on genetical and immunological criteria. Two groups of subjects, Am and Ay, can be distinguished. For the individuals of the first group, named Am, 15 samples (7 families) have been studied, the phenotype is inherited as an allele at the ABO locus. 14 of these subjects, have an alpha-N-acetylgalactosaminyltransferase whose kinetic properties were similar to those of A1 subjects. In one family, however, the A transferase detected is of the A1 type. On a quantitative level, the enzyme activities of these sera only reached 30-50 percent of the average value observed for A1 or A2 subjects, respectively. These facts suggest the existence of a genetic inhibitor, possibly linked to the ABO locus, preventing either an A1 or A2 gene from acting at the level of some cellular lines and leading therefore to the recognition of phenotypes named A-m-A1 and A-m-A2. On the contrary, under the experimental conditions used, no alpha-N-acetylgalactosaminyl-transferase activity was detected among the four individuals of the second group, named A-y by Weiner et al. (37), and whose appeareance in siblings results from the action of a recessive modifying y-A gene.

show abstract

“…Of the two A,B blood samples shown in table I, one of them, 'A2B', is an example of a fairly common type that must be avoided for assessing anti-A potency especially by avidity tests, as these are examples of suppressed A,B bloods [17] that have a far stronger A status than true A,B bloods. Elution at 56 O C [9] after absorption of the 18-fold anti-A concentrate at 4 O C using A,, A,, A,, A,, A, and control 0 cells, revealed a marked difference from studies with human serum anti-A reagents [7,9].…”

Section: Potency and A Specificitymentioning

confidence: 99%

Monoclonal Anti‐A from a Hybrid‐Myeloma: Evaluation as a Blood Grouping Reagent

Voak¹,

et al. 1980

Self Cite

View full text Add to dashboard Cite

A monoclonal anti-A antibody has been evaluated and found suitable for use as a potent routine ABO grouping reagent, without the use of additives. The IgM anti-A (MH2/6D4) is secreted into the tissue culture supernatant by a permanent line of cloned cells derived by fusion of anti-A producing spleen cells and a mouse myeloma cell line. This is a cost-effective reagent which should reduce production costs by over 50%. This reagent has the advantages inherent in monoclonal antibodies among them the availability of unlimited quantities of unvarying antibody of known properties.

show abstract

Observations on a New Example of the A(m) Phenotype which Demonstrates Reduced A Secretion

Cited by 5 publications

References 17 publications

Assay of α-TV-Acetylgalactosaminyltransferases in Human Sera

Assay of α-TV-Acetylgalactosaminyltransferases in Human Sera

Assay of α‐N‐Acetylgalactosaminyltransferases in Human Sera: Further Evidence for Several Types of A_m Individuals

Monoclonal Anti‐A from a Hybrid‐Myeloma: Evaluation as a Blood Grouping Reagent

Contact Info

Product

Resources

About

Observations on a New Example of the A(m) Phenotype which Demonstrates Reduced A Secretion

Cited by 5 publications

References 17 publications

Assay of α-TV-Acetylgalactosaminyltransferases in Human Sera

Assay of α-TV-Acetylgalactosaminyltransferases in Human Sera

Assay of α‐N‐Acetylgalactosaminyltransferases in Human Sera: Further Evidence for Several Types of Am Individuals

Monoclonal Anti‐A from a Hybrid‐Myeloma: Evaluation as a Blood Grouping Reagent

Contact Info

Product

Resources

About

Assay of α‐N‐Acetylgalactosaminyltransferases in Human Sera: Further Evidence for Several Types of A_m Individuals